Trial Profile

A Phase 2, Randomized, Placebo-Controlled Trial to Assess the Efficacy and Safety of Mosliciguat in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 15 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mosliciguat (Primary)
Indications Pulmonary hypertension
Focus Therapeutic Use
Acronyms PHocus
Sponsors Pulmovant

Most Recent Events

08 Sep 2026 According to a Roivant media release, results presented at the European Respiratory Society (ERS) International Congress 2026.
08 Sep 2026 Primary endpoint has been met. (Change from Baseline to Week 16 in Pulmonary Vascular Resistance (PVR)), according to a Roivant Media Release.
08 Sep 2026 Results presented in the Roivant Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com